{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:05:24Z","timestamp":1774555524568,"version":"3.50.1"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2003,10,7]],"date-time":"2003-10-07T00:00:00Z","timestamp":1065484800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Aventis"},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Centocor"},{"name":"Pharmacia"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate total direct medical costs in persons with rheumatoid arthritis (RA) and to characterize predictors of these costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (n = 7,527) participating in a longitudinal study of outcome in RA completed 25,050 semiannual questionnaires from January 1999 through December 2001. From these we determined direct medical care costs converted to 2001 US dollars using the consumer price index. We used generalized estimating equations to examine potential predictors of the costs. Monte Carlo simulations and sensitivity analyses were performed to evaluate the varying prevalence and cost of biologic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean total annual direct medical care cost in 2001 for a patient with RA was $9,519. Drug costs were $6,324 (66% of the total), while hospitalization costs were only $1,573 (17%). Approximately 25% of patients received biologic therapy. The mean total annual direct cost for patients receiving biologic agents was $19,016 per year, while the cost for those not receiving biologic therapy was $6,164. RA patients who were in the worst quartile of functional status, as measured by the Health Assessment Questionnaire, experienced direct medical costs for the subsequent year that were $5,022 more than the costs incurred by those in the best quartile. Physical status as determined by the Short Form 36 physical component scale had a similar large effect on RA costs, as did comorbidity. Medical insurance type played a more limited role. However, those without insurance had substantially lower service utilization and costs, and health maintenance organization patients had lower drug costs and total medical costs. Increased years of education, increased income, and majority ethnic status were all associated with increased drug costs but not hospitalization costs. Costs in all categories decreased after age 65 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Estimates of direct medical costs for patients with RA are substantially higher than cost estimates before the biologic therapy era, and costs are now driven predominantly by the cost of drugs, primarily biologic agents. RA patients with poor function continue to incur substantially higher costs, as do those with comorbid conditions, and sociodemographic characteristics also play an important role in determination of costs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.11439","type":"journal-article","created":{"date-parts":[[2004,6,2]],"date-time":"2004-06-02T14:21:02Z","timestamp":1086186062000},"page":"2750-2762","source":"Crossref","is-referenced-by-count":221,"title":["Direct medical costs and their predictors in patients with rheumatoid arthritis"],"prefix":"10.1002","volume":"48","author":[{"given":"Kaleb","family":"Michaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Messer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119080-00003"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780210714"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290405"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749109096811"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.8.791"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.8.781"},{"key":"e_1_2_5_8_2","first-page":"47","article-title":"The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates","volume":"44","author":"Yelin E","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_5_9_2","first-page":"1051","article-title":"Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study","volume":"24","author":"Clarke AE","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400816"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.8.837"},{"key":"e_1_2_5_12_2","first-page":"1156","article-title":"Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis","volume":"27","author":"Newhall\u2010Perry K","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M"},{"key":"e_1_2_5_14_2","first-page":"719","article-title":"Direct medical costs unique to people with arthritis","volume":"24","author":"Gabriel SE","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10471"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(00)80017-7"},{"key":"e_1_2_5_17_2","first-page":"467","article-title":"Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX\u20102 therapy","volume":"29","author":"Wolfe F","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_5_18_2","first-page":"1015","article-title":"Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX\u20102 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis","volume":"29","author":"Wolfe F","year":"2002","journal-title":"J Rheumatol"},{"issue":"9","key":"e_1_2_5_19_2","first-page":"S132","article-title":"The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice","volume":"41","author":"Wolfe F","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_5_20_2","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries JF","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_5_22_2","first-page":"1407","article-title":"The prevalence and meaning of fatigue in rheumatic disease","volume":"23","author":"Wolfe F","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780250903"},{"key":"e_1_2_5_24_2","first-page":"785","article-title":"The AIMS approach to health status measurement: conceptual background and measurement properties","volume":"9","author":"Meenan RF","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380612"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<53::AID-ANR8>3.0.CO;2-O"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.3.321"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.9.807"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"9","key":"e_1_2_5_33_2","first-page":"S76","article-title":"Utility measures in rheumatic diseases","volume":"46","author":"Choi HK","year":"2002","journal-title":"Arthritis Rheum"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00130-8"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08213-2"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00424-3"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200101000-00009"},{"key":"e_1_2_5_38_2","volume-title":"Medicare and Medicaid statistics","author":"Centers for Medicare and Medicaid Services","year":"2002"},{"key":"e_1_2_5_39_2","volume-title":"Drug topics red book","year":"2001"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200203000-00007"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.6.703"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70201-5"},{"key":"e_1_2_5_44_2","volume-title":"Stata statistical software: release 7.0","author":"Stata Corporation","year":"2001"},{"key":"e_1_2_5_45_2","unstructured":"TomzM WittenbergJ KingG.CLARIFY: software for interpreting and presenting statistical results.1998(1.2)."},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.11439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.11439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T12:31:40Z","timestamp":1697027500000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.11439"}},"subtitle":["A three\u2010year study of 7,527 patients"],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1002\/art.11439"],"URL":"https:\/\/doi.org\/10.1002\/art.11439","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}